14 Treatment with tyrosine kinase inhibitors make PBMCs from patients with chronic myeloid leukemia less susceptible to HIV-1 infection: control of CD4+ T cell activation to control HIV-1 replication
Saved in:
Main Authors: | Mercedes Bermejo (Author), Juan Ambrosioni (Author), Guiomar Bautista (Author), Núria Climent (Author), Elena Mateos (Author), Cristina Rovira (Author), Rafael Duarte (Author), Francisco Cervantes (Author), Montserrat Plana (Author), José M. Miró (Author), José Alcamí (Author), Mayte Coiras (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2017-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of tyrosine kinase inhibitors on the cytotoxic activity against HIV-1 infection
by: S. Rodríguez-Mora, et al.
Published: (2017) -
CD4 T cells from patients with chronic myeloid leukemia are resistant to HIV-1 proviral integration and transcription after prolonged withdrawal of treatment with tyrosine kinase inhibitors
by: Lorena Vigón, et al.
Published: (2019) -
Peripheral blood lymphocytes from patients with chronic myeloid leukemia on treatment with dasatinib are resistant to HIV-1 infection
by: M. Coiras, et al.
Published: (2015) -
Tyrosine kinase inhibition: the new front in HIV cure efforts
by: V. Planelles, et al.
Published: (2019) -
Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
by: Andrea Rodríguez-Agustín, et al.
Published: (2023)